IBRX vs JPM Stock Comparison
IBRX currently leads JPM in this stock comparison, with AIQ scores of 58 vs 53. The clearest difference is quality, while JPM has the stronger risk resilience profile.
What is the main difference between IBRX and JPM?
IBRX leads the current stock comparison as ImmunityBio, Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
ImmunityBio, Inc. vs JPMorgan Chase & Co.
IBRX leads
IBRX leads by 5 AIQ points, primarily on Quality, but the lead has narrowed from 19 points over 30 sessions.
Fragile: 4 of 6 evidence groups support IBRX, its lead is narrowing, and its current signal state is conflicted.
ImmunityBio, Inc.
JPMorgan Chase & Co.
The Algovestiq AIQ Score currently favors IBRX over JPM, 58 versus 53 as of Oct 31, 2026. IBRX's advantage is driven primarily by stronger quality, while JPM holds the stronger risk resilience profile. IBRX also shows the weaker technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor IBRX today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 5 points. IBRX lead: Weakening — the AIQ differential moved from 19 to 5 points over 30 sessions.
Compare ImmunityBio, Inc. and JPMorgan Chase & Co. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare IBRX and JPM against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality100 vs 46IBRX +54
- Risk Resilience28 vs 69JPM +41
- Value34 vs 44JPM +10
- Momentum53 vs 61JPM +8
4 of 6 evidence groups favor IBRX. IBRX’s edge is concentrated in quality; JPM keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-10-28, compared against the prior scored session 2026-10-27.
Largest factor move: Momentum +14
New signals
- Uptrend Structure Active — bullish, trend, long horizon
Largest factor move: Momentum +2
New signals
- BB Upper Band Breach — bearish, volatility, short horizon
IBRX's lead widened by 3 AIQ points in the latest session.
Deeper signal detail for each name lives on its own signals page — IBRX and JPM both carry a full feed there.
The central trade-off
IBRX (ImmunityBio, Inc.): the stronger current systematic profile, led by quality.
JPM (JPMorgan Chase & Co.): the counter-case, on risk resilience, value, momentum.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
IBRXIBRX on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
IBRXIBRX on combined revenue and EPS growth.
Value
JPMJPM on the peer-relative Value factor, by 10 points.
Momentum
JPMJPM on the Momentum factor, by 8 points.
Lower downside
JPMJPM on Risk Resilience, by 41 points.
Analyst upside
IBRXIBRX on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | IBRX | JPM | Note |
|---|---|---|---|
| Implied upside to target | +68.9% | +10.7% | IBRX has more room |
| Target dispersion | +28.6% | +32.2% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 3 | 11 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor IBRX. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | IBRX | 58 vs 53 |
| Fundamentals | IBRXon balance | revenue growth 15.9% vs -7.6%; EPS growth 64.5% vs -27.6%; TTM ROE 135% vs 17.9%; gross margin 94.6% vs 63.2%; operating margin -151.9% vs 28.2% — IBRX takes 4 of 5 decided legs, not all of them |
| Valuation | JPM | Value 34 vs 44 |
| Technicals | IBRX | Price vs 50-day -4.6% vs -2%; vs 200-day 12.3% vs 5.2% |
| Risk Resilience | JPM | Risk Resilience 28 vs 69 |
| Analyst expectations | IBRX | Target upside 68.9% vs 10.7% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of IBRX and JPM and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 5 points. (argues the conclusion is provisional)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The lead has swung materially session to session. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on IBRX.
How the comparison changed
120 daily snapshots · Jun 29 – Oct 28IBRX lead: Weakening — the AIQ differential moved from 19 to 5 points over 30 sessions.
- Today
- IBRX +5
- 58 vs 53
- 7 sessions ago
- IBRX +2
- 52 vs 50
- 30 sessions ago
- IBRX +19
- 63 vs 44
- 90 sessions ago
- IBRX +13
- 65 vs 52
The lead changed hands once in this window, most recently on Jul 22 when JPM moved ahead of IBRX.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 1 bearish / 2 neutral, conflicted
Only IBRX
- Bollinger Band Squeeze — neutral, volatility, short horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (7.83%)
- Uptrend Structure Active — bullish, trend, long horizon
- MACD Bearish Crossover — bearish, momentum, short horizon
2 bullish / 1 bearish, conflicted
Only JPM
- BB Upper Band Breach — bearish, volatility, short horizon
- MACD Bullish Crossover — bullish, momentum, short horizon
Both carry 1 more signal that do not separate them: Golden Cross Active.
IBRX leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price is down while the AIQ Score moved up 4 points over the same session — price and model disagree (price -5.15%, AIQ +4 points).
Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -1.9%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1JPM closes the Quality gap — currently 54 points behind, the largest single contributor to IBRX's edge.
- 2JPM's BB Upper Band Breach resolves — a bearish volatility rule currently active against it.
- 3IBRX's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once.
- 4The narrowing continues — the lead has already given back 14 points over 30 sessions, and a further 5-point move would eliminate IBRX's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
IBRX leads on balance| Metric | IBRX | JPM |
|---|---|---|
| Revenue growth (YoY) | 15.9% | -7.6% |
| EPS growth (YoY) | 64.5% | -27.6% |
| Gross margin | 94.6% | 63.2% |
| Operating margin | -151.9% | 28.2% |
| Return on equity (TTM) | 135% | 17.9% |
| Debt to equity | -0.78 | 3.32 |
Performance
IBRX leads 5 of 6 windows| Metric | IBRX | JPM |
|---|---|---|
| 1 week (5 sessions) | 2% | 1.2% |
| 1 month (20 sessions) | -6.7% | 2.6% |
| 3 months (63 sessions) | 18.3% | -3.3% |
| 6 months (126 sessions) | 26.6% | 9.7% |
| Year to date | 344.9% | 5.3% |
| 1 year (252 sessions) | 256.7% | 12.9% |
Technicals
IBRX has the stronger structure| Metric | IBRX | JPM |
|---|---|---|
| RSI (14) | 39.8 | 60.9 |
| ADX (14) | 24.8 | 15 |
| Price vs 50-day | -4.6% | -2% |
| Price vs 200-day | 12.3% | 5.2% |
| Volatility (1M, annualized) | 84.7% | 13% |
Risk
JPM is the more resilient| Metric | IBRX | JPM |
|---|---|---|
| Beta | 1.61 | 0.73 |
| Sharpe ratio | 1.61 | 0.41 |
| Sortino ratio | 3.3 | 0.56 |
| Max drawdown | -42.3% | -15.5% |
| Current drawdown | -23.7% | -7.1% |
| Annualized volatility | 107.2% | 22% |
| Value at risk (95%) | -7.4% | -2.4% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, IBRX or JPM?
On the Algovestiq AIQ Score, IBRX is the stronger of the two as of Oct 31, 2026, scoring 58 against JPM's 53. The edge comes from quality. JPM is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is IBRX or JPM the better buy right now?
IBRX carries the stronger systematic profile as of Oct 31, 2026, and the comparison is rated Fragile — 4 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 5 points. Treat the lead as provisional.
Why does the AIQ Score favor IBRX over JPM?
The composite weights Quality, Value, Momentum and Risk Resilience. IBRX leads Quality by 54 points; JPM leads Risk Resilience by 41 points; JPM leads Value by 10 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, IBRX or JPM?
Analyst price targets imply +68.9% upside for IBRX and +10.7% for JPM, so the Street currently favors IBRX. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, IBRX or JPM?
JPM is the better-valued of the two on the peer-relative Value factor. JPM on the peer-relative Value factor, by 10 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, IBRX or JPM?
IBRX on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, IBRX or JPM?
JPM on the Momentum factor, by 8 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, IBRX or JPM?
JPM is the more resilient of the two, so the other name carries the higher downside risk. JPM on Risk Resilience, by 41 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is IBRX more profitable than JPM?
The profitability evidence is mixed: gross margin 94.6% vs 63.2%; operating margin -151.9% vs 28.2%; ttm roe 135% vs 17.9%. IBRX leads on two measures and JPM on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is IBRX's lead over JPM getting stronger or weaker?
IBRX lead: Weakening — the AIQ differential moved from 19 to 5 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-29 and 2026-10-28. The lead has changed hands once in that window, most recently on 2026-07-22, when JPM moved ahead of IBRX.
What would change the IBRX vs JPM verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: JPM closes the Quality gap — currently 54 points behind, the largest single contributor to IBRX's edge; JPM's BB Upper Band Breach resolves — a bearish volatility rule currently active against it; IBRX's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 14 points over 30 sessions, and a further 5-point move would eliminate IBRX's advantage entirely.
What do the current signals say about IBRX and JPM?
IBRX: 2 bullish / 1 bearish / 2 neutral, conflicted. JPM: 2 bullish / 1 bearish, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on IBRX is Golden Cross Active (bullish, long horizon). On JPM it is Golden Cross Active (bullish, long horizon).
Compare IBRX and JPM with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.